Given the clear preclinical activity in B-cell lymphoma models, INO was also tested in CD22-positive ALL models, where it induced complete tumor regression and cures in mice, warranting its clinical development in ALL [5, 6]. This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.